iwCLL 2017 | Why is it important to risk stratify patients in CLL?

Kostas Stamatopoulos

Kostas Stamatopoulos, MD, PhD from the Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece provides an overview of chronic lymphocytic leukemia (CLL) at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY. Dr Stamatopoulos discusses the significant progress in CLL and how physicians go about stratifying patients in order allocate specific treatments to improve outcomes. He also mentions where research should be directed in the future.

Share this video